Acrivon Therapeutics (ACRV) Stock Chart & Stock Price History $2.15 +0.65 (+43.33%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$2.16 +0.01 (+0.47%) As of 04/15/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Acrivon Therapeutics Stock Price Performance 5 Day Performance+32.72%1 Month Performance-60.48%3 Month Performance-61.26%6 Month Performance-72.26%Year-To-Date Performance-64.29%1 Year Performance-77.30% Receive ACRV Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Acrivon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ACRV Stock Chart for Wednesday, April, 16, 2025 ACRV Chart by TradingViewRemove Ads Acrivon Therapeutics Stock Price History Daily Weekly Monthly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization04/15/2025$1.50$2.15+43.33%$2.19$1.501.52 million shs$67.41 million04/14/2025$1.62$1.50-7.41%$1.73$1.49218,692 shs$47.03 million04/11/2025$1.53$1.62+5.88%$1.62$1.45108,711 shs$50.79 million04/10/2025$1.61$1.53-4.97%$1.63$1.44165,939 shs$47.97 million04/09/2025$1.36$1.61+18.38%$1.67$1.30246,480 shs$50.48 million04/09/2025$1.36$1.61+18.38%$1.67$1.30246,480 shs$50.48 million04/08/2025$1.39$1.36-2.16%$1.70$1.32293,968 shs$42.64 million04/08/2025$1.39$1.36-2.16%$1.70$1.32293,968 shs$42.64 million04/07/2025$1.51$1.39-7.95%$1.64$1.36166,233 shs$43.58 million04/04/2025$1.64$1.51-7.93%$1.68$1.40317,556 shs$47.02 million Get the Latest News and Ratings for ACRV and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Acrivon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 04/03/2025$1.74$1.64-5.75%$1.72$1.53174,456 shs$51.06 million04/02/2025$1.68$1.74+3.57%$1.90$1.62288,759 shs$54.18 million04/01/2025$2.03$1.68-17.24%$1.99$1.56567,597 shs$52.31 million03/31/2025$2.24$2.03-9.38%$2.30$2.02273,965 shs$63.21 million03/28/2025$2.52$2.24-11.11%$2.52$2.14434,076 shs$69.75 million03/27/2025$2.61$2.52-3.45%$2.97$2.44522,448 shs$78.46 million03/26/2025$5.39$2.61-51.58%$4.42$2.511.86 million shs$81.27 million03/25/2025$5.61$5.39-3.92%$5.62$5.3545,414 shs$167.82 million03/24/2025$5.36$5.61+4.66%$5.65$5.2539,756 shs$174.67 million03/21/2025$5.14$5.36+4.28%$5.40$5.0064,738 shs$166.89 million03/20/2025$5.46$5.14-5.86%$5.52$5.1414,471 shs$160.04 million03/19/2025$5.36$5.46+1.87%$5.62$5.2021,762 shs$170.00 million03/18/2025$5.50$5.36-2.55%$5.42$5.2915,296 shs$166.89 million03/17/2025$5.44$5.50+1.10%$5.57$5.3216,522 shs$171.25 million Related Companies Terns Pharmaceuticals Stock Chart Cardiff Oncology Stock Chart Gossamer Bio Stock Chart Design Therapeutics Stock Chart Tevogen Bio Stock Chart TuHURA Biosciences Stock Chart MediWound Stock Chart LifeVantage Stock Chart Voyager Therapeutics Stock Chart Eledon Pharmaceuticals Stock Chart Receive ACRV Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Acrivon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:ACRV) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acrivon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acrivon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.